Augmedix, Inc. AUGX
We take great care to ensure that the data presented and summarized in this overview for Augmedix, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AUGX
View all-
Redmile Group, LLC San Francisco, CA16.4MShares$15.1 Million2.64% of portfolio
-
Dcm International Vi, Ltd.4.17MShares$3.84 Million5.31% of portfolio
-
Samjo Capital LLC2.91MShares$2.68 Million5.93% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.89MShares$1.74 Million0.0% of portfolio
-
Perkins Capital Management Inc1.46MShares$1.34 Million5.15% of portfolio
-
Cowen Prime Advisors LLC1.34MShares$1.23 Million2.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.3MShares$1.2 Million0.0% of portfolio
-
Balyasny Asset Management LLC Chicago, IL1.18MShares$1.09 Million0.01% of portfolio
-
Parkman Healthcare Partners LLC Stamford, CT1.07MShares$980,8200.59% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.04MShares$961,3700.0% of portfolio
Latest Institutional Activity in AUGX
Top Purchases
Top Sells
About AUGX
Augmedix, Inc. provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live and Augmedix Notes solutions that provide pre-visit documentation, such as pre-charting and digitization of previous records/patient history; during-visit documentation, including medical notes, care gap reminders, HCC reminders, and after-visit summaries; and post-visit documentation consisting of coding, orders, and referrals. The company enables clinicians to access its applications through mobile devices, such as smartphones or Google Glass. It serves health systems and specialty groups. The company was founded in 2013 and is headquartered in San Francisco, California.
Insider Transactions at AUGX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 14
2024
|
Redmile Group, LLC Director |
BUY
Grant, award, or other acquisition
|
Indirect |
12,879
+0.08%
|
-
|
|
Jun 14
2024
|
Robert C. Faulkner Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,879
+23.7%
|
-
|
|
May 15
2024
|
Sandra Breber CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
2,354
-12.55%
|
$2,354
$1.19 P/Share
|
|
May 15
2024
|
Sandra Breber CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+25.0%
|
-
|
|
May 15
2024
|
Emmanuel Krakaris PRESIDENT, CEO, AND SECRETARY |
SELL
Open market or private sale
|
Direct |
3,528
-5.65%
|
$3,528
$1.19 P/Share
|
|
May 15
2024
|
Emmanuel Krakaris PRESIDENT, CEO, AND SECRETARY |
BUY
Exercise of conversion of derivative security
|
Direct |
9,375
+13.06%
|
-
|
|
May 15
2024
|
Jonathan Hawkins CHIEF REVENUE OFFICER |
SELL
Open market or private sale
|
Direct |
1,767
-37.69%
|
$1,767
$1.19 P/Share
|
|
May 15
2024
|
Jonathan Hawkins CHIEF REVENUE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,688
+50.0%
|
-
|
|
May 15
2024
|
Paul Ginocchio CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,354
-1.75%
|
$2,354
$1.19 P/Share
|
|
May 15
2024
|
Paul Ginocchio CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+4.45%
|
-
|
|
May 15
2024
|
Ian Shakil CHIEF STRATEGY OFFICER |
SELL
Open market or private sale
|
Direct |
1,387
-20.55%
|
$1,387
$1.19 P/Share
|
|
May 15
2024
|
Ian Shakil CHIEF STRATEGY OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+35.71%
|
-
|
|
May 15
2024
|
Saurav Chatterjee CHIEF TECHNOLOGY OFFICER |
SELL
Open market or private sale
|
Direct |
1,767
-37.69%
|
$1,767
$1.19 P/Share
|
|
May 15
2024
|
Saurav Chatterjee CHIEF TECHNOLOGY OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,688
+50.0%
|
-
|
|
Apr 15
2024
|
Ian Shakil CHIEF STRATEGY OFFICER |
SELL
Open market or private sale
|
Direct |
500
-14.29%
|
$1,500
$3.8 P/Share
|
|
Apr 15
2024
|
Ian Shakil CHIEF STRATEGY OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
500
+12.5%
|
$0
$0.86 P/Share
|
|
Apr 12
2024
|
Ian Shakil CHIEF STRATEGY OFFICER |
SELL
Open market or private sale
|
Direct |
19,544
-86.69%
|
$58,632
$3.82 P/Share
|
|
Apr 12
2024
|
Ian Shakil CHIEF STRATEGY OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
19,544
+46.44%
|
$0
$0.86 P/Share
|
|
Apr 11
2024
|
Ian Shakil CHIEF STRATEGY OFFICER |
SELL
Open market or private sale
|
Direct |
24,778
-89.2%
|
$74,334
$3.93 P/Share
|
|
Apr 11
2024
|
Ian Shakil CHIEF STRATEGY OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
24,778
+47.15%
|
$0
$0.86 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 84.2K shares |
|---|---|
| Open market or private purchase | 1.51M shares |
| Exercise of conversion of derivative security | 228K shares |
| Open market or private sale | 455K shares |
|---|